Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a growth of 15% compared to the previous year[13]. - The company's operating revenue for 2022 was ¥570,855,435.18, a decrease of 22.28% compared to ¥734,479,885.95 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥46,908,665.33, an improvement of 18.54% from -¥57,581,886.98 in 2021[19]. - The total revenue for 2022 was CNY 570.86 million, a decrease of 22.28% compared to the previous year[54]. - The pharmaceutical sector generated CNY 562.19 million in revenue, representing 98.48% of total revenue and a decline of 20.05% year-on-year[56]. - The company reported a significant increase in cash flow from operations, indicating potential for improved liquidity and operational efficiency moving forward[19]. - The company achieved a net increase in cash and cash equivalents of ¥1,122,599,535.77 in 2022, a significant improvement from a decrease of ¥349,738,061.95 in 2021, reflecting a 420.98% change[71]. - The company reported a total investment of 91,611.08 million CNY for various projects, achieving 100% of the planned investment[86]. User Growth and Market Expansion - User data showed a rise in active users, reaching 5 million, which is an increase of 20% year-on-year[13]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for 2023, indicating a projected growth of 25%[13]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in these regions[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[132]. - The company plans to enhance its digital platform, aiming for a 40% increase in online sales channels[132]. Research and Development - The company plans to invest 100 million RMB in R&D for new technologies over the next year[13]. - The company has established four specialized pharmaceutical research institutions with approximately 200 experienced R&D personnel, focusing on technological innovation and new drug development[43]. - The company has over 200 R&D personnel working on more than 20 projects, including several innovative drug candidates[50]. - The company is in the preclinical research phase for a new innovative drug targeting acute ischemic stroke, aiming for IND submission in approximately 1.5 years[67]. - The company has made progress in developing CBD-based treatments for rare diseases, with patent grants in major global markets[67]. - The company plans to accelerate the progress of R&D projects in 2023, with specific targets including entering clinical stages for the WYY project and ZT project, and achieving production approval for Trimetazidine Hydrochloride Tablets[100]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local health tech firm was completed, valued at 300 million RMB, to enhance technological capabilities[13]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[127]. - The company has established partnerships with two major distributors to enhance its supply chain efficiency[127]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency by reducing costs by 5% through process optimization initiatives[13]. - The company is actively pursuing cost reduction strategies, resulting in significant decreases in raw material costs[52]. - The company will implement cost reduction and efficiency enhancement strategies in 2023, aiming to improve capacity utilization and reduce unit costs through better supplier management and production technology innovation[101]. Risk Management - The management has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company faces risks from market and policy changes, particularly due to the ongoing reforms in the pharmaceutical industry and stricter regulations[103]. - The company will manage production cost risks by establishing long-term partnerships with quality suppliers and innovating production processes[104]. Governance and Compliance - The company maintains complete operational independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, and finance[112]. - The company has established a comprehensive financial management system, with independent accounting practices and tax obligations, ensuring no interference from the controlling shareholder[113]. - The company has a complete governance structure, with independent directors holding a majority in key committees, ensuring fair treatment of all shareholders[111]. - The company is committed to improving its governance structure by appointing qualified individuals to its board and management team[120]. Environmental Responsibility - The company has achieved compliance with national standards for pollution discharge in its production activities, with specific pollutant discharge limits outlined[172]. - The company has completed environmental impact report approvals for multiple projects, including the high Qing production base and Huan Tai medical beauty project[172]. - The company achieved a 100% compliance rate for wastewater discharge, meeting both Beijing and local sewage discharge standards[181]. - JiaLin Pharmaceutical invested approximately 2.01 million yuan in environmental governance and protection in 2022[180]. Shareholder Relations and Profit Distribution - No cash dividends will be distributed to shareholders for the fiscal year 2022, as the company focuses on reinvestment[4]. - The company reported a net profit attributable to shareholders of -46,908,665.33 CNY for 2022, with an initial undistributed profit of 3,894,471,040.61 CNY[151]. - The profit distribution plan for 2022 was deemed reasonable and compliant with relevant regulations, ensuring the protection of minority shareholders' interests[153]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,082, with 30 in the parent company and 1,052 in major subsidiaries[147]. - The company has implemented various training programs, including professional skills training and safety management, targeting different employee groups[150]. - The company emphasizes the importance of adjusting the shareholding structure before project initiation to prevent external shareholders from influencing future investments[146].

Financial Performance - The company's revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.90% compared to ¥192,816,625.91 in the same period last year[5] - Net profit attributable to shareholders was ¥1,859,373.76, down 93.89% from ¥30,445,095.31 year-on-year[5] - The net cash flow from operating activities was ¥49,861,633.81, a decline of 61.77% compared to ¥130,435,562.96 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0008, representing a decrease of 94.12% from ¥0.0136 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.9% compared to ¥192,816,625.91 in the same period last year[22] - Net profit for Q1 2023 was ¥582,608.11, a significant decline from ¥22,929,114.75 in Q1 2022, representing a decrease of 97.5%[24] - Total comprehensive income for the period amounted to CNY 582,608.11, a decrease from CNY 22,929,114.75 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,554,524,795.94, down 2.11% from ¥5,674,395,997.63 at the end of the previous year[5] - Total assets decreased to ¥5,554,524,795.94 from ¥5,674,395,997.63, a reduction of 2.1%[21] - Total liabilities decreased to ¥328,445,794.71 from ¥390,381,648.39, a decline of 15.9%[21] Cash Flow - The company's cash and cash equivalents increased to ¥2,985,284,796.13 from ¥2,599,135,458.30 at the beginning of the year, reflecting a growth of 14.8%[20] - Cash inflow from investment activities reached CNY 400,005,200.00, significantly higher than CNY 80,551,396.03 in the previous period, indicating a growth of 396.5%[27] - Net cash flow from investment activities was CNY 386,383,653.20, compared to a negative CNY 15,445,078.29 in the previous period, showing a substantial turnaround[27] - Total cash inflow from operating activities was CNY 187,407,681.48, down from CNY 299,649,594.13 in the previous period, a decline of about 37.4%[26] - Total cash outflow from operating activities was CNY 137,546,047.67, compared to CNY 169,214,031.17 in the previous period, a decrease of approximately 18.7%[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,330[12] - Major shareholders include Meilin Holdings Group with 19.11% and Shanghai Yueye Equity Investment Management with 18.60%[13] - The company’s major shareholder, Meilin Holdings, holds 425,470,400 shares, representing 19.11% of the total share capital[17] - The company’s top ten shareholders include significant stakes from Xinjiang Kaidi Investment and Xinjiang Kaidi Mining, with holdings of 409,748,445 shares and 104,039,367 shares respectively[14] - The company’s top ten shareholders have a combined holding of 1.17% in the repurchase special account[15] Share Repurchase - As of March 31, 2023, the company repurchased a total of 26,105,140 shares, accounting for 1.17% of the total share capital, with a total payment of RMB 91,674,284 (excluding transaction fees)[15] - The company has repurchased a total of 25,323,440 shares, with the highest transaction price at RMB 3.88 per share and the lowest at RMB 2.94 per share, totaling RMB 88,756,868 (excluding transaction fees)[17] - The company’s total share repurchase reached 24,823,440 shares, approximately 1.11% of the total share capital, with a total payment of RMB 86,881,868 (excluding transaction fees)[16] - The company’s stock repurchase plan allows for a maximum reduction of 22,263,945 shares, not exceeding 1% of the total share capital[17] Investment and Projects - The company plans to invest approximately RMB 489.36 million in the Hainan Dezheng International Medical and Health Complex project, with a total construction area of about 71,828 square meters and a construction period of 33 months[17] - The company’s subsidiary, Jialin Pharmaceutical, participated in the eighth national centralized procurement and is expected to win the bid for Amlodipine Atorvastatin Calcium Tablets[17] Research and Development - Research and development expenses for Q1 2023 were ¥11,907,421.27, an increase of 11.1% compared to ¥10,715,438.38 in Q1 2022[22] Financial Expenses - The company reported a financial expense of -¥19,002,480.13, compared to -¥13,068,207.92 in the previous year, indicating an increase in financial costs[24] Audit Status - The first quarter report was not audited[28]

证券代码： 000813 证券简称：天山纺织 编号：2014-09-25 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | | 上海证券报：樊英利、刘宏鹏、郑培源、徐晶晶、周鲁； | | 人员姓名 | | 西南证券：柯靓、於铀强、张煦。 | | 时间 | 2014 年 9 月 25 | 日上午 10： 30-12:30 点 | | 地点 | 公司 3 楼会议室 | | | 上市公司接待人 | | 董事长：武宪章；总经理：王广斌；副总经理：余熊来；副 | | 员姓名 | | 总经理、董秘：魏哲明；证券事务代表：蒋欣 ...

证券代码： 000813 证券简称：天山纺织 编号：2015-04-03 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-06-27 | --- | --- | --- | --- | |--------------------|-----------------------------------|----------------------------------------------|-------| | | | | | | | √ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ 其他 （请文字说明其他活动内容） | | | | | 安信证券：崔文亮、孔令岩、肖寒 | | | | | | 中信证券资管：吴晓雯、于聪 国寿安保：刘志军 | | | | | 囯信证券：江维娜、徐巍 华商基金：张晓 华夏基 | | | 参与单位名称及人员 | 金：杨杨 嘉实基金：高兰君 | | | | | | 九州证券：岳志强 神农投资：殷南秋 | | | 姓名 | | 农银人寿：冯安铭、周建 ...

证券代码： 000813 证券简称：天山纺织 编号：2016-09-08 新疆天山毛纺织股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------|------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 （ ） | | | 参与单位名称及 | 西南证券：周平 | | | 人员姓名 | 建信养老基金：蒋锦 | | | | 东兴证券：胡偌碧 | | | | | 信达证券：单丹、张华、钟惠、胡申、李惜浣 | | | 新华汇嘉：戴泽龙 | | | | 中邮基金：陈梁 | | | | 中银基金：梦圆 | | | | 天风证券：廖庆阳 | | | | 建信基金：陈洁馨 | | | | 新华基金：潮礼君 | | | | 东方证券：季序我 | | | | 天弘基金：刘 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-07-18 | --- | --- | --- | |--------------------|-----------------------------------------------|------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | | | 华创证券：张文录、孙 渊 东方基金：欧阳娟 | | 参与单位名称及人员 | | 天安保险：金春萍 征金资本：唐爽爽 | | 姓名 | | 星石投资：何豪杰 玺萌财富：王齐越 | | | | 盛盈资本：袁清慧 渤海汇金证券：张雷 | | 时 间 | 2017 年 7 月 18 日 | 30 分至 17 点 | | 地 点 | 公司会议室 | | | 公司接待人员姓名 | 董 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2017-11-7 | --- | --- | --- | |--------------------|----------------------------------|---------------------------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 （请文字说明其他活动内容） | | | | | 中欧基金：卢博森 兴业证券：杜向阳 | | 参与单位名称及人员 | | 国投瑞银：谢允昌 国寿安保基金：刘志军、李丹 | | | | 国寿资产：丁天宇、赵文龙 华榛投资：杨清 | | 姓名 | | 泓德基金：操昭煦 工银瑞信：卢静 | | | | 信诚基金：郑伟 鹏华基金：葛谨洁 | | 时 间 | 2017 年 11 月 7 日 | 点 30 分至 17 点 15 分 | | 地 点 | 公 ...

证券代码：000813 证券简称：德展健康 德展大健康股份有限公司投资者关系活动记录表 编号：2018-6-27 | --- | --- | --- | |--------------------|-----------------------------------------|-----------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 东方证券：刘恩阳 孙瞳 邓振 王凯乐 苗喆 王丽颖 | | 参与单位名称及人员 | | 浙银合一：王聪 霍伟 方正证券：卫马清 | | 姓名 | | 国泰基金：姜英 金满汇投资：李太辉 | | | | 玖麟投资：张东麟 侯重阳 北京亚宝投资：郭常平 | | | | 高特佳：张维亮 嘉实基金：颜媛 | | 时 间 | 2018 年 6 月 27 | 日 15 点 30 分至 1 ...

证券代码：000813 证券简称：德展健康 2018 年 12 月 6 日投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|--------------------|--------|----------------------------------------------------| | | | | | | | √ | | 特定对象调研 □分析师会议 | | | □ | | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | | | □其他 （请文字说明其他活动内容） | | | | | 中信建投：贺菊颖 刘若飞 神农投资：王宇美 | | 参与单位名称及人员 | | | 信诚基金：王岩 华商基金：孙蔚 | | | | | 浙银合一：王聪 渤海资管：陈洣璠 | | 姓名 | | | 鸿道投资：王泳金 中信证券：罗啦 | | | | | 渤海汇金：纪钢 泰信基金：徐慕浩 | | 时 间 | 2018 年 12 | 月 6 | 日 16:00 点 00 分至 ...